Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Moderate Suppurative Hidradenitis
NCT03049267Phase 2Completed
- Sponsor
- M.B.A. van Doorn
- Start
- Feb 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apremilast in hidradenitis suppurativa (HS), sponsored by M.B.A. van Doorn. Started Feb 2017; status: completed.
02
Drugs
apremilast
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03049267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049267.